Day-one subcutaneous Leqembi means starting Leqembi Iqlik (lecanemab-irmb), a drug that targets amyloid-beta in early Alzheimer's disease, with weekly shots instead of starting with IV infusions. Family caregivers can prepare by confirming eligibility, arranging brain scans and lab testing, securing drug supply, and setting a monitoring plan before the first dose.
According to Eisai, the FDA approved the supplemental application for subcutaneous Leqembi Iqlik as an initiation dose on July 13, 2026, as described in Eisai's July 13 announcement. That change allows treatment to begin outside the infusion center. Preparation still centers on safety checks and follow-up care.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who can start treatment?
- What does the first home dose involve?
- How do you arrange safety monitoring?
- What supply, training, and coverage steps come before day one?
Who can start treatment?
Treatment is only for adults with mild cognitive impairment or mild dementia due to Alzheimer's disease with confirmed amyloid-beta pathology. According to the FDA, this is the same early-stage group studied in trials, described in the FDA approval notice. Caregivers should obtain the clinic note, diagnosis stage, and amyloid test result before ordering drug.
A confirmed result matters because symptoms alone do not establish eligibility. Keep copies of cognitive testing, diagnosis letters, and pathology reports in one folder. Bring that folder to every prescribing and coverage appointment.
What does the first home dose involve?
The initiation regimen is 500 mg once weekly, given as two consecutive 250-mg autoinjector injections of about 15 seconds each. According to Eisai, maintenance is 360 mg once weekly after 18 months of IV or subcutaneous treatment, as detailed in Eisai's dosing summary. Caregivers should practice handling, timing, skin-site selection, and dose documentation during device training.
Patients may stay on IV or subcutaneous dosing for the whole course and may switch between them. Eisai reports this flexibility lets families plan home doses versus infusion-center visits. Ask the prescriber to write the current route, dose, and switch plan in the care instructions.
How do you arrange safety monitoring?
Leqembi carries a boxed warning for amyloid-related imaging abnormalities, called ARIA, with brain swelling and bleeding. The FDA label requires a recent baseline brain MRI and scheduled MRI checks during treatment. Schedule the baseline scan early, confirm where follow-up scans will occur, and keep emergency contacts posted at home. For IV Leqembi, the FDA recommended in August 2025 an earlier MRI before the third infusion, plus MRIs before the 5th, 7th, and 14th infusions, to catch swelling early.
Ask the prescribing team which MRI dates apply when starting with subcutaneous dosing. Do not start without written scan dates and a plan for reporting headache, confusion, dizziness, vision change, nausea, or weakness. Testing for ApoE epsilon 4 status should occur before starting. FDA labeling notes higher ARIA incidence, including symptomatic and severe events, in ApoE epsilon 4 homozygotes. Record the result with the MRI schedule and review what it means for watchfulness with the clinician.
What supply, training, and coverage steps come before day one?
Eisai said Leqembi Iqlik for initiation would move through U.S. specialty pharmacy starting in late August 2026, so fulfillment, delivery, and device training need advance planning, as reported in the BioSpace/Eisai release. Call the specialty pharmacy early to confirm prescription receipt, shipment date, storage steps, and injection teaching.
Keep the pharmacy, prescriber, and MRI center numbers together. Medicare covers FDA-approved anti-amyloid antibodies including lecanemab only under Coverage with Evidence Development. The Centers for Medicare and Medicaid Services requires enrollment in an approved registry or study. Ask the clinic which registry applies, who enters the data, and what consent is needed.
- Confirm diagnosis stage and amyloid result
- Complete ApoE testing and baseline MRI
- Secure specialty-pharmacy order, delivery date, and device training
- File registry consent and coverage approval
- Post dose dates, MRI dates, and warning signs where caregivers can see them
You Might Also Like
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: Access, Cost, and Follow-Up Questions for Primary Care Patients
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: Access, Cost, and Follow-Up Questions for Primary Care Patients
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: Access, Cost, and Follow-Up Questions for Primary Care Patients
